Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV000626664 | SCV000747366 | uncertain significance | Muscle weakness; Hypokalemia; Hypermagnesemia; Myalgia | 2017-01-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001860477 | SCV002273792 | likely pathogenic | not provided | 2023-11-28 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 153 of the SLC12A3 protein (p.Val153Met). This variant is present in population databases (rs779074538, gnomAD 0.01%). This missense change has been observed in individuals with Gitelman syndrome (PMID: 17654016, 31672324). This variant is also known as c.463G>A, p.Val153Met. ClinVar contains an entry for this variant (Variation ID: 523358). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC12A3 protein function with a positive predictive value of 95%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
MGZ Medical Genetics Center | RCV002289914 | SCV002580466 | uncertain significance | Familial hypokalemia-hypomagnesemia | 2021-10-25 | criteria provided, single submitter | clinical testing |